COVID19_BMT

Study design/Summary: This is a non interventional, prospective, multicentre study.

Objectives: The study aims to document the clinical and biological characteristics, including immunological profiling, of allogeneic stem cell transplant recipients presenting with severe COVID 19 infection and its impact on survival. This work may provide the scientific basis for targeted therapy with biological agents in this patient group.

Centres:

• University Hospitals Bristol NHS Foundation Trust
• The Royal Marsden NHS Foundation Trust
• University College London Hospitals NHS Foundation Trust
• Great Ormond Street Hospital NHS Foundation Trust
• Manchester University NHS Foundation Trust
• Cardiff and Vale UHB
• University Hospitals Birmingham NHS Foundation Trust
• King’s College Hospital, London
• Heartlands, Birmingham
• Hammersmith Hospital, London
• Nottingham City Hospital
• The Christie, Manchester
• Derriford Hospital, Plymouth
• Clatterbridge Cancer Centre, Liverpool
• St James’s University Hospital Hospital, Leeds
• Churchill Hospital, Oxford
• Queen Elizabeth University Hospital, Glasgow

Target number of patients: up to 100 patients

Patient population: Adult and paediatric patents (of any age) who have received allogeneic stem cell transplant and have a proven COVID-19 infection

Sponsorship/Funding: Great Ormond Street Hospital, Bristol Myers Squibb, NIHR Blood and Transplant Research Unit & University of Birmingham, funded by the IMPACT network

Trial Status: Closed

Links:

Trial Protocol

Lay Summary of Study Results

ClinicalTrials.gov

Trial Contacts:

covid19bmt@trials.bham.ac.uk

Research.Governance@gosh.nhs.uk

Start date: 04-May-2020

Duration: Recruiting until June 2021

If you are a patient and interested in taking part in a clinical trial, please speak with your consultant who will be able to offer you further information and discuss whether it is suitable for you. A referral from your medical team would be required in order to consider you for treatment on a clinical trial.